Athersys’ MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in … – NASDAQ
|
Athersys’ MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in …
NASDAQ The Company is developing its MultiStem cell therapy as a GvHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell (HSC) transplant and is currently preparing for a Phase II/III clinical study in the area. The MultiStem therapy for … Athersys Treatment for Stem Cell Transplant Complication Gets Orphan Status in …Wall Street Journal Athersys: EMA issues positive opinion on MultiStem Cell therapyRTT News |
